We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
51
Teva Pharmaceuticals
TEVA
$42.5B
$8.08M 0.48%
268,391
+32,420
+14% +$1.04M
SVRA icon
52
Savara
SVRA
$1.08B
$8M 0.47%
1,464,535
+59,083
+4% +$329K
MPLT
53
MapLight Therapeutics
MPLT
$584M
$7.62M 0.45%
+374,909
New +$6.71M
LONA
54
LeonaBio Inc
LONA
$74.8M
$7.48M 0.44%
727,481
+333,780
+85% +$2.17M
EQ icon
55
Equillium
EQ
$152M
$7.45M 0.44%
3,726,659
-1,881,419
-34% -$3.1M
VKTX icon
56
Viking Therapeutics
VKTX
$3.75B
$7.41M 0.44%
227,717
+201,223
+760% +$6.47M
DMRA
57
Damora Therapeutics
DMRA
$1.79B
$7.23M 0.43%
+279,000
New +$7.17M
URGN icon
58
UroGen Pharma
URGN
$2.13B
$7.11M 0.42%
395,459
+270,084
+215% +$5.41M
BBIO icon
59
BridgeBio Pharma
BBIO
$15B
$7M 0.41%
94,292
-119,122
-56% -$8.63M
PRME icon
60
Prime Medicine
PRME
$655M
$6.87M 0.4%
+1,973,282
New +$7.51M
IWM icon
61
PUT
iShares Russell 2000 ETF
IWM
$80.8B
$6.82M 0.4%
27,500
– –
VRTX icon
62
Vertex Pharmaceuticals
VRTX
$137B
$6.73M 0.4%
15,075
+1,359
+10% +$634K
KRRO icon
63
Korro Bio
KRRO
$190M
$6.11M 0.36%
+540,054
New +$5.95M
VRDN icon
64
Viridian Therapeutics
VRDN
$2.61B
$5.95M 0.35%
304,422
+227,224
+294% +$6.75M
DHR icon
65
Danaher
DHR
$152B
$5.86M 0.35%
30,932
+5,332
+21% +$1.14M
INSM icon
66
Insmed
INSM
$25.9B
$5.79M 0.34%
+35,392
New +$5.44M
ASND icon
67
Ascendis Pharma A/S
ASND
$16.3B
$5.72M 0.34%
25,014
-300
-1% -$67.3K
BHF icon
68
Brighthouse Financial
BHF
$3.05B
$5.72M 0.34%
95,523
– –
SRPT icon
69
Sarepta Therapeutics
SRPT
$2.2B
$5.7M 0.34%
262,058
+233,192
+808% +$4.51M
OACCU
70
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$5.5M 0.32%
516,482
– –
PCSC
71
DELISTED
Perceptive Capital Solutions
PCSC
$5.48M 0.32%
499,581
+42,861
+9% +$547K
KRYS icon
72
Krystal Biotech
KRYS
$10.4B
$5.17M 0.3%
20,014
– –
ABOS icon
73
Acumen Pharmaceuticals
ABOS
$211M
$5.09M 0.3%
2,156,334
+1,265,151
+142% +$3.23M
IVVD icon
74
Invivyd
IVVD
$284M
$4.97M 0.29%
3,822,427
-76,970
-2% -$141K
BHAVU
75
BHAV Acquisition Corp Units
BHAVU
$4.93M 0.29%
+495,000
New +$4.93M
1 2
3
4 5

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.